Fisetin did not improve 6-minute walk distance in peripheral artery disease pilot trial.
Pilot randomized trial of 34 people with peripheral artery disease assigned to fisetin or placebo. The trial tested whether fisetin would reduce senescent cell markers in blood and tissue and improve 6-minute walk distance. The abstract reports the study design and proposed analyses but does not report actual results or whether fisetin affected walking distance, senescent markers, or inflammatory markers.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 15, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 34
- Duration
- —
- Population
- People with peripheral artery disease (PAD)
- Primary outcome
- Reduction in abundance of senescent cells in blood, skeletal muscle, and subcutaneous and inter muscular adipose tissue; improvement in 6-minute walk distance
- Effect size
- —
- Significance
- Not reported
- Journal
- Northwestern University
- Published
- Apr 15, 2026
Sources
Primary source
- Northwestern University ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.